Literature DB >> 15243118

Fungemia caused by Zygoascus hellenicus in an allogeneic stem cell transplant recipient.

Mary E Brandt1, Carol A Kauffman, Peter G Pappas, Naureen Iqbal, Beth A Arthington-Skaggs, Wendy Lee-Yang, Maudy T Smith.   

Abstract

Zygoascus hellenicus (Candida hellenica) was isolated from a blood culture from a patient who had received an allogeneic stem cell transplant. The isolate displayed an antifungal susceptibility pattern of decreased susceptibility to fluconazole and itraconazole, high susceptibility to voriconazole, and low susceptibility to caspofungin. The organism was misidentified by a commercial yeast identification system. This is the first reported case of human infection with this rare ascomycetous yeast.

Entities:  

Mesh：

Year:  2004        PMID： 15243118      PMCID： PMC446251          DOI： 10.1128/JCM.42.7.3363-3365.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Pseudooutbreak of Candida versatilitis fungemia in a microbiology laboratory.

Authors:  Mary E Brandt; Lynette E Benjamin; Gregory E Steinkraus
Journal:  Diagn Microbiol Infect Dis       Date:  2003-05       Impact factor: 2.803

3.  The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.

Authors:  A S Kao; M E Brandt; W R Pruitt; L A Conn; B A Perkins; D S Stephens; W S Baughman; A L Reingold; G A Rothrock; M A Pfaller; R W Pinner; R A Hajjeh
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

4.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

Authors:  K A Marr; K Seidel; T C White; R A Bowden
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

Review 5.  New and emerging yeast pathogens.

Authors:  K C Hazen
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5' end of the large-subunit (26S) ribosomal DNA gene.

Authors:  C P Kurtzman; C J Robnett
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

7.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.

Authors:  J H Rex; M A Pfaller; A L Barry; P W Nelson; C D Webb
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

Review 10.  Importance of Candida species other than C. albicans as pathogens in oncology patients.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079
View more
  1 in total

1.  The Frequency, Antifungal Susceptibility and Enzymatic Profiles of Candida Species Isolated from Neutropenic Patients.

Authors:  Maral Gharaghani; Ali Rezaei-Matehkolaei; Ali Zarei Mahmoudabadi; Bijan Keikhaei
Journal:  Jundishapur J Microbiol       Date:  2016-10-09       Impact factor: 0.747
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.